Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
70actual
Sites
14
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-07 | actual | When the study began enrolling |
| Primary completion | 2025-04-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-11 | actual | The whole study's end, after follow-up |
| First posted | 2022-11-30 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-27 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Invasive Fungal Disease
Intervention
- Drug: Isavuconazole — also filed as Cresemba®
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
measured From start of study intervention on Day 1 up to 28 days after last dose of study intervention (For Isavuconazole IA group: approximately up to 112 days, for Isavuconazole IM group: approximately up to 208 days)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-01-29 · 6.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-03-13 · 4.2 MB · SAP_001.pdf
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed